Tony Berberabe, MPH

Articles

First Effective Adjuvant Treatment Identified in High-Risk Prostate Cancer

May 31st 2015

Treatment with an adjuvant combination of docetaxel, androgen deprivation therapy (ADT), and radiation therapy (RT) improved 4-year overall survival rates in patients with high-risk localized prostate cancer, when compared with ADT plus RT alone.

3rd Annual Giants of Cancer Care Class Brings Together Diverse Honorees

May 29th 2015

After weeks of deliberations, the final votes have been cast and the winners of the 2015 Giants of Cancer Care® can now be revealed.

Physicians Struggle With Antiquated Reimbursement for Next-Generation Testing

May 22nd 2015

The growing use of genetic biomarker tests to screen, monitor, diagnose, and treat patients with cancer has the potential to improve outcomes and reduce costs, but payment systems for covering and reimbursing for these tests have fallen behind the times.

Combined Imaging Approach Effectively Detects Aggressive Prostate Cancer

May 18th 2015

The combination of multiparametric MRI with a fusion-guided biopsy (MRI plus ultrasound) was more effective at detecting aggressive prostate cancer compared with either procedure alone.

Sexual Function Scores Are Better After Robotic Versus Open Surgery for Prostate Cancer

May 18th 2015

Sexual function scores were better for patients who had a robotic compared with open surgery for prostate cancer; however, comparative results for urinary function were not conclusive.

'Chilling Effect' Seen After USPSTF Recommends Against Routine PSA Testing

May 17th 2015

Since the USPSTF guideline on PSA screening the overall rate of PSA testing decreased by 50% among primary care physicians at Oregon Health & Science University.

Active Surveillance Protocols Needed for Prostate Cancer

May 16th 2015

As the AS strategy gains a foothold among urologists both here in the US and around the world, a study presented at the 110th Annual Scientific Meeting of the American Urological Association suggests that among men in the US, very few are following the stringent protocol for AS that is recommended by major academic institutions.

Presence of AR-V7 in Stromal, Epithelial Tissue Suggests Role in Carcinogenesis

May 16th 2015

The role of androgen receptor variant-7 in patients with early stage prostate cancer is not well characterized but data presented at the 2015 American Urological Association (AUA) Meeting is bringing the discussion into focus.

Olaparib Nears 90% Response in Molecular Subgroup of mCRPC

April 21st 2015

Treatment with olaparib demonstrated a durable overall response rate of 87.5% in a biomarker-defined subgroup of men with pretreated sporadic metastatic castration-resistant prostate cancer in a phase II multi-step adaptive trial.

Tasquinimod Development in mCRPC Halted After Phase III Study Falls Short

April 16th 2015

Topline results announced today from the phase III Swedish trial 10TASQ10 demonstrated that tasquinimod failed to extend overall survival in men with metastatic castrate-resistant prostate cancer.

STRIVE Data Further Demonstrate PFS Benefit With Enzalutamide Over Bicalutamide

April 2nd 2015

Treatment with enzalutamide reduced the risk of progression by 76% compared with bicalutamide in men with castration-resistant prostate cancer.

Advanced Bladder Cancer Increases Suicide Risk, Study Says

March 27th 2015

Older, single white males with advanced bladder cancer have the highest suicide risk among those with other cancers of the male genitals and urinary system, researchers report.

PREVAIL, TERRAIN Updates Show Improved OS With Enzalutamide

March 24th 2015

Two studies investigating enzalutamide in men with early stage metastatic castration-resistant prostate cancer further confirmed the overall survival and progression-free survival benefit of the agent over placebo.

Studies of Second-Line Immunotherapies in Bladder Cancer Hold Promise

March 16th 2015

With no major advances in survival in bladder cancer in more than 30 years, interest is high in the potential to deploy immunotherapeutic approaches in this setting.

Task Force PSA Recommendation Needs Updating, LUGPA President Says

March 16th 2015

A United States Preventive Services Task Force recommendation against the use of prostate specific antigen testing needs to be updated, said Gary Kirsh, MD, president of the Large Urology Group Practice Association.

Making Sense of the Prostate Cancer Screening Debate

March 14th 2015

Leonard G. Gomella, MD, told attendees at the 8th Annual IPCC that the decision to screen or not to screen for prostate cancer boiled down to "using common sense, shared decision making, and choosing the right patients to screen."

PD-1 Agents Vie for Frontline Spot in Melanoma Immunotherapy

February 27th 2015

New checkpoint blockade agents that target the PD-1 pathway are moving forward quickly in the melanoma treatment paradigm and likely will become a frontline immunotherapy choice for patients with advanced or metastatic disease, according to Jason J. Luke, MD, FACP, a leading researcher in the field.

Chemotherapy for CLL Not Yet Obsolete But in Flux as New Agents Gain Ground

February 21st 2015

Standard chemotherapy remains part of the treatment paradigm for patients with chronic lymphocytic leukemia but its role is undergoing a major shift as significant advances are being made in novel therapies.

ASCO Supports ACS Guidelines for Prostate Cancer Survivor Care

February 15th 2015

ASCO has endorsed new prostate cancer survivorship care guidelines from the American Cancer Society that provide a structure to help prostate cancer specialists and primary care physicians deliver high quality of care to patients with localized disease.

Oral Chemotherapy Use Benefits From Safety Self-Assessments

February 9th 2015

The Institute for Safe Medication Practices (ISMP) and the Institute for Safe Medication Practices Canada (ISMP Canada) worked collaboratively to create a self-assessment tool to assist oncologists in evaluating safe practices related to medication use.